Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 7, 2016, Pages 673-683

  Billiet, T ^a   Cleynen, I ^a   Ballet, V ^b   Ferrante, M ^a,b   Van Assche, G ^a,b   Gils, A ^c   Vermeire, S ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BODY MASS; COLON DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAILURE FREE SURVIVAL; FEMALE; HUMAN; ILEUM DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SURVIVAL PREDICTION; SURVIVAL RATE; TERTIARY HEALTH CARE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CROHN DISEASE; FEMALE; HUMANS; INFLIXIMAB; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84991383780     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13754     Document Type: Article

References (30)

1. Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014; 14: 75–101.
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–95.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
4. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015; 64: 1539–45.
5. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320–9. e3.
6. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–66.
7. Juillerat P, Sokol H, Froehlich F, et al. Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis 2015; 21: 60–70.
8. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492–500.
9. Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013; 19: 1622–30.
10. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721–7.
11. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147: 1296–307 e5.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
13. D'Haens GR, Vermeire S, Lambrecht G, et al. Drug-Level based dosing versus symptom-based adaptation in patients with Crohn's disease: a prospective, randomized multicenter study (TAILORIX). Gastroenterology 2016; 150: S143.
14. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765–71.
15. Van Stappen T, Brouwers E, Tops S, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit 2015; 37: 479–85.
16. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. Epidemiology 2010; 21: 128–38.
17. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28–62.
18. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987–95.
19. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962–71.
20. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357–63.
21. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617–25.
22. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70. e5; quiz e31.
23. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568–76.
24. Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis 2012; 18: 2011–7.
25. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
26. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239–50.
27. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014; 20: 1714–21.
28. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing shortterm and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451–7.
29. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014; 39: 1126–35.
30. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management. Aliment Pharmacol Ther 2015; 43: 30–51.